ArticleActa neuropathologica communications2019
Transcriptome signatures associated with meningioma progression.
Article in Acta neuropathologica communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- Epigenetic Alterations in Meningiomas-A Review.Biomedicines · 2026Review
- Integrative transcriptomics and network analysis reveals core genes driving meningioma pathogenesis and clinical outcomes.Scientific reports · 2025Article
- Determining the Biological Features of Aggressive Meningioma Growth with Transcriptomic Profiling.Cancers · 2025Article
- The chemical composition of Diwu YangGan capsule and its potential inhibitory roles on hepatocellular carcinoma by microarray-based transcriptomics.Journal of traditional and complementary medicine · 2024Article
- Meningioma transcriptomic landscape demonstrates novel subtypes with regional associated biology and patient outcome.Cell genomics · 2024Article
- Inhibition of BMP signaling pathway induced senescence and calcification in anaplastic meningioma.Journal of neuro-oncology · 2024Article
- Gene transcript fusions are associated with clinical outcomes and molecular groups of meningiomas.Acta neuropathologica · 2024Article
- CTAT-LR-fusion: accurate fusion transcript identification from long and short read isoform sequencing at bulk or single cell resolution.bioRxiv : the preprint server for biology · 2024Article
- Gene expression analysis during progression of malignant meningioma compared to benign meningioma.Journal of neurosurgery · 2023Article
- Paths of Evolution of Progressive Anaplastic Meningiomas: A Clinical and Molecular Pathology Study.Journal of personalized medicine · 2023Article
- Advances in Central Nervous System Tumor Classification.Advances in experimental medicine and biology · 2023Article
- Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas.Neuro-oncology · 2022Article
- Multiple approaches converge on three biological subtypes of meningioma and extract new insights from published studies.Science advances · 2022Article
- Article
- Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets.Diagnostics (Basel, Switzerland) · 2021Review
- Deep Learning Model for the Automated Detection and Histopathological Prediction of Meningioma.Neuroinformatics · 2021Article
- Article
- Alteration of FOXM1 expression and macrophage polarization in refractory meningiomas during long-term follow-up.Translational cancer research · 2021Article
- Article
- Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma.Nature communications · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 1 country.
Funding
Abstract
Meningiomas are the most common primary brain tumor of adults. The majority are benign (WHO grade I), with a mostly indolent course; 20% of them (WHO grade II and III) are, however, considered aggressive and require a more complex management. WHO grade II and III tumors are heterogeneous and, in some cases, can develop from a prior lower grade meningioma, although most arise de novo. Mechanisms leading to progression or implicated in de novo grade II and III tumorigenesis are poorly understood. RNA-seq was used to profile the transcriptome of grade I, II, and III meningiomas and to identify genes that may be involved in progression. Bioinformatic analyses showed that grade I meningiomas that progress to a higher grade are molecularly different from those that do not. As such, we identify GREM2, a regulator of the BMP pathway, and the snoRNAs SNORA46 and SNORA48, as being significantly reduced in meningioma progression. Additionally, our study has identified several novel fusion transcripts that are differentially present in meningiomas, with grade I tumors that did not progress presenting more fusion transcripts than all other tumors. Interestingly, our study also points to a difference in the tumor immune microenvironment that correlates with histopathological grade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.